Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-12
2005-07-12
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S300000, C514S333000, C544S105000, C544S335000, C546S081000, C546S082000, C546S122000, C546S256000, C546S115000, C546S118000, C548S306100
Reexamination Certificate
active
06916810
ABSTRACT:
The present invention relates to cyclic urea derivatives, their synthesis, and their use as αv integrinreceptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, tumor growth and metastasis.
REFERENCES:
patent: 6017926 (2000-01-01), Askew et al.
patent: 6066648 (2000-05-01), Duggan et al.
patent: 6268378 (2001-07-01), Duggan et al.
patent: WO 96/31485 (1996-10-01), None
patent: WO 99/30709 (1998-06-01), None
patent: WO 99/31099 (1999-06-01), None
Database CA on STN, Chem. Abstracts (Columbus, OH), Accession No. 135:137508, Duggan et al., “Preparation of oxoimidazzolidinecarboxylates as .alpha. ν integrin receptor antagonists”, abstract WO 2001053297, Jul. 26, 2001.
Database CA on STN, Chem. Abstracts (Columbus, OH), Accession No. 134:366793, Jensen et al., “Process and intermediates for the preparation of imidazolidinone alpha ν integrin antagonists”, abstract WO 2001034602, May 2001.
Database CA on STN, Chem. Abstracts (Columbus, OH), Accession No. 131:58814, Duggan et al., “Naphthyridine derivatives of pyrrolidinylpropiionic acid and analogs useful as integrin receptor antagonists”, abstract WO 9930709, Jun. 1998.
Hutchinson John H.
Li Aiwen
Daniel Mark R.
Merck & Co. , Inc.
Seaman D. Margaret
Shatynski Patricia A.
LandOfFree
αν integrin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with αν integrin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and αν integrin receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3409738